Tick-borne Encephalitis Vaccine Failures: A 10-year Retrospective Study Supporting the Rationale for Adding an Extra Priming Dose in Individuals Starting at Age 50 Years

Abstract Background Southern Sweden is endemic for tick-borne encephalitis (TBE), with Stockholm County as one of the high-risk areas. Our aim in this study was to describe cases of vaccine failures and to optimize future vaccination recommendations. Methods Patients with TBE were identified in the notification database at the Department of Communicable Disease Control and Prevention in Stockholm County during 2006–2015. Vaccine failure was defined as TBE despite adherence to the recommended vaccination schedule with at least 2 doses. Clinical data were extracted from medical records. Results A total of 1004 TBE cases were identified, 53 (5%) were defined as vaccine failures. In this latter group, the median age was 62 years (6–83). Forty-three (81%) patients were aged >50 years and 2 were children. Approximately half of the patients had comorbidities, with diseases affecting the immune system accounting for 26% of all cases. Vaccine failures following the third or fourth vaccine dose accounted for 36 (68%) of the patients. Severe and moderate TBE disease affected 81% of the cases. Conclusions To our knowledge, this is the largest documented cohort of TBE vaccine failures. Vaccine failure after 5 TBE vaccine doses is rare. Our data provide rationale for adding an extra priming dose to those aged ≥50 years.

[1]  U. Meyding-Lamadé,et al.  Clinical outcome and cerebrospinal fluid profiles in patients with tick-borne encephalitis and prior vaccination history. , 2018, Ticks and tick-borne diseases.

[2]  F. Strle,et al.  The long-term outcome of tick-borne encephalitis in Central Europe. , 2017, Ticks and tick-borne diseases.

[3]  J. Brzostek,et al.  Seropersistence of TBE virus antibodies 10 years after first booster vaccination and response to a second booster vaccination with FSME-IMMUN 0.5mL in adults. , 2017, Vaccine.

[4]  F. Strle,et al.  Tick‐borne encephalitis in patients vaccinated against this disease , 2017, Journal of internal medicine.

[5]  A. Nirkko,et al.  Fatal Outcome of European Tick-borne Encephalitis after Vaccine Failure , 2017, Front. Neurol..

[6]  M. Sturzenegger,et al.  Tick-borne Encephalitis (TBE) , 2017, Neurology International Open.

[7]  M. Petzold,et al.  Tick‐Borne Encephalitis sequelae at long‐term follow‐up: a self‐reported case–control study , 2016, Acta neurologica Scandinavica.

[8]  L. Rombo,et al.  Tick-borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study. , 2016, Vaccine.

[9]  K. Rostásy,et al.  Tick‐borne encephalitis in a child with previous history of completed primary vaccination , 2016, Pediatrics international : official journal of the Japan Pediatric Society.

[10]  M. Insulander,et al.  Tick borne encephalitis (TBE)-vaccination coverage and analysis of variables associated with vaccination, Sweden. , 2015, Vaccine.

[11]  P. Forsberg,et al.  Factors Determining Immunological Response to Vaccination against Tick-Borne Encephalitis Virus in Older Individuals , 2014, PloS one.

[12]  U. Heininger,et al.  Epidemiology of tick-borne encephalitis in Switzerland, 2005 to 2011. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  M. Kundi,et al.  Factors associated with seroimmunity against tick borne encephalitis virus 10 years after booster vaccination. , 2013, Vaccine.

[14]  M. L. Cristina,et al.  Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines , 2013, Human vaccines & immunotherapeutics.

[15]  K. Stiasny,et al.  Vaccination and Tick-borne Encephalitis, Central Europe , 2013, Emerging infectious diseases.

[16]  C. Siegrist 2 – Vaccine immunology , 2013 .

[17]  H. Ehrlich,et al.  Antibody persistence after two vaccinations with either FSME-IMMUN® Junior or ENCEPUR® Children followed by third vaccination with FSME-IMMUN® Junior , 2012, Human vaccines & immunotherapeutics.

[18]  M. Niedrig,et al.  Tick-borne encephalitis in Europe, 2007 to 2009. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[19]  J. Süss Tick-borne encephalitis 2010: epidemiology, risk areas, and virus strains in Europe and Asia-an overview. , 2011, Ticks and tick-borne diseases.

[20]  T. Avšič-Županc,et al.  Tick-borne encephalitis after vaccination: vaccine failure or misdiagnosis. , 2010, Vaccine.

[21]  K. Stiasny,et al.  Decreased antibody titers and booster responses in tick-borne encephalitis vaccinees aged 50-90 years. , 2010, Vaccine.

[22]  Å. Lundkvist,et al.  Vaccine failures after active immunisation against tick-borne encephalitis. , 2010, Vaccine.

[23]  K. Stiasny,et al.  Characteristics of antibody responses in tick-borne encephalitis vaccination breakthroughs. , 2009, Vaccine.

[24]  L. Lindquist,et al.  Tick-borne encephalitis in Sweden in relation to aseptic meningo-encephalitis of other etiology: a prospective study of clinical course and outcome , 1997, Journal of Neurology.

[25]  F. Strle,et al.  Tick-borne encephalitis after active immunization , 2008 .

[26]  O. Vapalahti,et al.  Tick-borne encephalitis , 2008, The Lancet.

[27]  I. Mutz,et al.  Tick‐borne encephalitis in Styrian children from 1981 to 2005: a retrospective study and a review of the literature , 2008, Acta paediatrica.

[28]  S. Krähenbühl,et al.  A fatal tick bite occurring during the course of tick-borne encephalitis vaccination. , 2008, The Pediatric Infectious Disease Journal.

[29]  S. Plíšek,et al.  TBE infection in an incomplete immunized person at-risk who lives in a high-endemic area--impact on current recommendations for immunization of high-risk groups. , 2008, Vaccine.

[30]  F. Heinz,et al.  Field effectiveness of vaccination against tick-borne encephalitis. , 2007, Vaccine.

[31]  U. Bogdahn,et al.  Delayed Humoral Immunity in a Patient with Severe Tick-borne Encephalitis after Complete Active Vaccination , 2007, Infection.

[32]  F. Strle,et al.  Mitteilungen der gesellschaft , 2012, Wiener klinische Wochenschrift.

[33]  M. Kundi,et al.  Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation. , 2004, Vaccine.

[34]  A. Bender,et al.  Two severe cases of tick-borne encephalitis despite complete active vaccination—the significance of neutralizing antibodies , 2004, Journal of Neurology.

[35]  C. Kunz TBE vaccination and the Austrian experience. , 2003, Vaccine.

[36]  Å. Lundkvist,et al.  Tickborne encephalitis in an area of high endemicity in lithuania: disease severity and long-term prognosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  R. Kaiser The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994-98: a prospective study of 656 patients. , 1999, Brain : a journal of neurology.

[38]  L. Lindquist,et al.  Intrathecal IgM, IgA and IgG antibody response in tick-borne encephalitis. Long-term follow-up related to clinical course and outcome. , 1997, Clinical and diagnostic virology.

[39]  L. Lindquist,et al.  A 10-year follow-up study of tick-borne encephalitis in the Stockholm area and a review of the literature: need for a vaccination strategy. , 1996, Scandinavian journal of infectious diseases.